01 8Biktarvy
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 7,259
2019 Revenue in Millions : 4,738
Growth (%) : 53
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 8,624
2020 Revenue in Millions : 7,259
Growth (%) : 19
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 8,624
2020 Revenue in Millions : 7,259
Growth (%) : 19
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2021 Revenue in Millions : 8,624
2020 Revenue in Millions : 7,259
Growth (%) : 19
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2022 Revenue in Millions : 10,390
2021 Revenue in Millions : 8,624
Growth (%) : 20
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2023 Revenue in Millions : 11,850
2022 Revenue in Millions : 10,390
Growth (%) : 14
Bictegravir, Emtricitabine, Tenofovir Alafenamide
Main Therapeutic Indication : Infectious Diseases (HIV, Hepatitis...
Currency : USD
2018 Revenue in Millions : 1,184
2017 Revenue in Millions : 0
Growth (%) : New Launch
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2019 Revenue in Millions : 4,738
2018 Revenue in Millions : 1,184
Growth (%) : 300
LOOKING FOR A SUPPLIER?